Venaxis (APPY) is a very interesting diagnostic substances company. The diagnostics are not necessarily the most glamorous part of the industry, and yet Venaxis has put itself in a position where it could provide significant return on investment for long-term oriented shareholders. Currently, the company has only one product in development, APPY 1. As APPY 1 advances through the clinical process, and as Venaxis switches its focus from product development to product commercialization, shareholders have the potential to benefit from significant long-term upside in Venaxis shares.
APPY 1 is Venaxis's diagnostic substance for the diagnosis of appendicitis. Currently, testing for appendicitis requires a multitude of tests in a hospital setting, which increase costs associated with the...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: